Department of Thoracic Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Department of Thoracic Surgery, Juntendo University School of Medicine, 3-1-3 Hongo, Bunkyo City, Tokyo, 113-0033, Japan.
Surg Today. 2024 Sep;54(9):1005-1014. doi: 10.1007/s00595-024-02804-2. Epub 2024 Mar 2.
Among non-small cell lung cancers (NSCLC), 5 years is a benchmark in cancer control and treatment, but a certain percentage of cases recur after 5 years. The long-term post-recurrence outcomes remain controversial. To examine the accurate prognostic factors associated with survival and cancer recurrence among 5-year survivors, a landmark analysis that considered competing risks was performed.
Complete resection of NSCLC was performed in 2482 patients between January 2003 and December 2015. A total of 1431 patients were 5-year survivors without recurrence. A landmark time analysis was applied to the overall survival (OS) and recurrence-free survival (RFS) from 5 years after surgery, and the findings were calculated using the Kaplan-Meier method. The cumulative incidence of cause-specific death and recurrence was estimated using the cumulative incidence function, while carefully considering the competing risks.
Postoperative recurrence was detected in 732 patients, of whom 68 (9.3%) had recurrence after 5 years. The median follow-up period was 8.2 years. In the competing risk analysis, the independent poor prognostic factors associated with cause-specific death were age ≥ 75 years, lymph node metastasis and pleural invasion.
Patients requiring a follow-up for > 5 years were aged ≥ 75 years and had either lymph node metastasis or pleural invasion.
在非小细胞肺癌(NSCLC)中,5 年是癌症控制和治疗的一个基准,但仍有一定比例的病例在 5 年后复发。长期复发后的结局仍存在争议。为了研究与 5 年生存者的生存和癌症复发相关的准确预后因素,进行了考虑竞争风险的里程碑分析。
2003 年 1 月至 2015 年 12 月期间,对 2482 例 NSCLC 患者进行了完全切除术。共有 1431 例患者为 5 年无复发的生存者。对手术后 5 年后的总生存(OS)和无复发生存(RFS)进行了里程碑时间分析,并使用 Kaplan-Meier 法计算了结果。使用累积发生率函数仔细考虑竞争风险,估计了特定原因死亡和复发的累积发生率。
732 例患者术后复发,其中 68 例(9.3%)在 5 年后复发。中位随访时间为 8.2 年。在竞争风险分析中,与特定原因死亡相关的独立不良预后因素为年龄≥75 岁、淋巴结转移和胸膜侵犯。
需要随访超过 5 年的患者为年龄≥75 岁且有淋巴结转移或胸膜侵犯的患者。